Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

INDUSTRY 5NETWORK 1

Study Type

Interventional 5

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 926Neoplasms 609Breast Neoplasms 604Colorectal Neoplasms 457Neoplasm Metastasis 394Ovarian Neoplasms 328Melanoma 312Prostatic Neoplasms 311Lung Neoplasms 294Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 228Leukemia, Myeloid, Acute 220Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 182Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 177Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 154Lymphoma, Follicular 148Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Interventions

Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Solid Malignancies × 1 year × Clear all
NCT06725381 2026-05-08

A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 1 Recruiting
138 enrolled

Solid Malignancies

NCT07505771 2026-04-06

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Immunome, Inc.

Phase EARLY_PHASE1 Recruiting
105 enrolled

Solid Malignancies

NCT05006794 2026-01-07

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Gilead Sciences

Phase 1 Active not recruiting
145 enrolled

Solid Malignancies

NCT06600789 2025-11-03

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

Carrick Therapeutics Limited

Phase 1/2 Recruiting
50 enrolled

Solid Malignancies

NCT06933069 2025-09-11

Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

Taizhou Mabtech Pharmaceutical Co.,Ltd

Phase 1 Recruiting
55 enrolled

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡